Lifetime risk for breast cancer is reduced in parous women compared to nulliparous women, provided that pregnancy occurs at a young age 1 . However, even with young age at first pregnancy, a transient increased risk for breast cancer is observed with each pregnancy 2 . Notably, the magnitude and duration of this increased risk is greater in older firsttime mothers 2 . Given the trend toward delayed childbearing observed in the US and all developing countries 3 , breast cancer diagnosed in recently pregnant women is expected to rise 4 . Furthermore, independent of the woman's age and tumor pathological characteristics, women diagnosed with breast cancer within 5 years postpartum have a higher incidence of breast cancer-related deaths compared to women who are diagnosed during pregnancy [5] [6] [7] [8] . These data indicate that a process subsequent to pregnancy, but not pregnancy itself, contributes to the poor prognosis of postpartum breast cancer.
Lifetime risk for breast cancer is reduced in parous women compared to nulliparous women, provided that pregnancy occurs at a young age 1 . However, even with young age at first pregnancy, a transient increased risk for breast cancer is observed with each pregnancy 2 . Notably, the magnitude and duration of this increased risk is greater in older firsttime mothers 2 . Given the trend toward delayed childbearing observed in the US and all developing countries 3 , breast cancer diagnosed in recently pregnant women is expected to rise 4 . Furthermore, independent of the woman's age and tumor pathological characteristics, women diagnosed with breast cancer within 5 years postpartum have a higher incidence of breast cancer-related deaths compared to women who are diagnosed during pregnancy [5] [6] [7] [8] . These data indicate that a process subsequent to pregnancy, but not pregnancy itself, contributes to the poor prognosis of postpartum breast cancer.
Decreased survival of women with postpartum breast cancer is often attributed to delayed diagnosis. Although delayed diagnosis is a clinical concern, a biological explanation for the poor prognosis of postpartum breast cancer is its promotion by physiological attributes that are unique to the postpartum mammary gland. After lactation, or after parturition in the absence of nursing, the mammary gland undergoes involution. Postpartum involution utilizes coordinated programs of epithelial cell death and stromal remodeling to result in gland architecture that resembles the nonsecretory state before pregnancy. Evidence shows that the involuting mammary gland has similar characteristics to wound healing and tumor-promotional microenvironments [9] [10] [11] [12] [13] [14] [15] [16] . To account for the poor prognosis of postpartum breast cancer, we have proposed that tumor cell exposure to the involuting mammary microenvironment promotes breast cancer metastasis 4, 9, 13, 17 .
Collagen deposition is an attribute of wound healing that is evident in the postpartum involuting gland 14 and is emerging as a key player in stromal-mediated tumor progression 18, 19 . The presence of fibrillar collagen correlates with increased risk for breast cancer, as well as tumor cell proliferation, invasion and metastasis 18, 20, 21 . When intestinal epithelial cells are exposed to collagen I, increased COX-2 expression and COX-2-dependent motility are observed 22 . COX-2 is an enzyme that promotes the production of prostaglandin mediators of inflammation 23 , and COX-2 is a well-established therapeutic target in colon cancer [24] [25] [26] . In individuals with breast cancer, elevated COX-2 expression is observed in ~40% of invasive cases and correlates with poor prognosis [27] [28] [29] [30] [31] [32] , ductal carcinoma in situ (DCIS) recurrence 33 and progression of hyperplasia 34 . In studies of breast cancer outcomes, COX-2 inhibition by NSAID use is associated with decreased breast cancer recurrence as well as a decrease in related deaths 35, 36 . In animal models, COX-2 overexpression induces 37 and knockout reduces 38 mammary tumorigenesis, and in vitro inhibition of COX-2 reduces breast cancer cell proliferation, migration and invasion 39 . Finally, in xenografted breast tumor cell populations, high COX-2 expression is associated with infiltration of the lungs 31 , bones 40 and brain 32 . Given the directly proportional relationship observed between collagen and COX-2 expression in the colon, the presence of increased collagen in the mammary gland during postpartum involution implicates COX-2 as a potential mediator of postpartum breast cancer.
The prognosis of breast cancer in young women is influenced by reproductive history. Women diagnosed within 5 years postpartum have worse prognosis than nulliparous women or women diagnosed during pregnancy. Here we describe a mouse model of postpartum breast cancer that identifies mammary gland involution as a driving force of tumor progression. In this model, human breast cancer cells exposed to the involuting mammary microenvironment form large tumors that are characterized by abundant fibrillar collagen, high cyclooxygenase-2 (COX-2) expression and an invasive phenotype. In culture, tumor cells are invasive in a fibrillar collagen and COX-2-dependent manner. In the involuting mammary gland, inhibition of COX-2 reduces the collagen fibrillogenesis associated with involution, as well as tumor growth and tumor cell infiltration to the lung. These data support further research to determine whether women at high risk for postpartum breast cancer would benefit from treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) during postpartum involution. To generate a mouse model of postpartum breast cancer that isolates the tumor-promotional effects of involution, we injected human breast tumor MCF10DCIS 41 cells into intact mouse mammary glands that were postpartum and actively involuting (involution group) or quiescent (nulliparous group). In the mammary gland, MCF10DCIS cells form lesions that are histologically similar to human DCIS lesions that progress to invasive cancers 41, 42 . Here we demonstrate that progression of MCF10DCIS cells to invasion is promoted by the involuting mammary microenvironment in a manner that is dependent on fibrillar collagen and COX-2. Furthermore, we report increased collagen deposition in postpartum involuting breast tissue from women, increased COX-2 protein expression in postpartum DCIS cases, and a correlation between collagen I and COX-2 tumor mRNA expression and disease-free survival, implicating this pathway in young women's breast cancer. On the basis of these observations, we used our mouse model to show that treatment with celecoxib and ibuprofen, restricted to the window of postpartum mammary gland involution, reverses the promotional effects of involution on mammary tumor progression.
RESULTS

Involution promotes tumor growth via collagen
Clinically, DCIS lesions are defined by malignant epithelial cells that are confined in the breast duct by an intact layer of myoepithelial cells, with disruption of the myoepithelial layer indicating progression to invasive carcinoma 43 . To develop a mouse model capable of assessing the impact of postpartum involution on DCIS progression, we injected human mammary epithelial tumor MCF10DCIS cells into intact mammary glands of immunodeficient (severe combined immune deficiency (SCID)) mice 1 d after weaning (involution group) or into mammary glands of age-matched nulliparous mice (nulliparous group). In this model, early DCIS-like lesions were evident as solid clusters of malignant cells that were separated from the mouse mammary stroma by a continuous layer of human-derived myoepithelium, consistent with previous reports 41, 42 . MCF10DCIS cells formed DCIS lesions that closely resembled clinically relevant histological subtypes, and progression to invasion correlated with loss of the myoepithelial cell layer. Invasive tumors were dominantly triple negative and basal-like 44, 45 ( Supplementary Fig. 1a-d) . At 4 weeks after tumor cell injection, the involution group mice had a greater than 200% increase in average tumor size ( Fig. 1a and Supplementary Fig. 1e,f) . We also observed tumor cell promotion by involution with two additional cell lines ( Supplementary Fig. 1e and H. Martinson, V.B. and P.S., unpublished data). Compared to the nulliparous group, the involution group also showed increases in tumor number (Fig. 1b) , tumor burden (Fig. 1c) and percentage of Ki67-positive tumor cells (Fig. 1d) , identifying the involuting mammary microenvironment as tumor promotional.
Noninjected SCID mouse mammary glands showed increased fibrillar collagen deposition during postpartum involution (Fig. 1e,f) , and involution group tumors had increased intratumor collagen deposition (Fig. 1g,h ). These data suggest that the collagen-rich microenvironment of the postpartum gland influences collagen deposition in the developing tumor. In vitro, tumor cells exposed to collagen I were more proliferative (Fig. 1i,j) , similar to that observed in involution group tumors (compare Fig. 1d to Fig. 1i; Supplementary Fig. 1g ), indicating that elevated deposition of collagen in the involuting mammary gland may contribute to the increased tumor growth observed in mice from the involution.
Involution promotes collagen-dependent tumor cell dispersion
To determine whether the increased number of tumors observed in the involution group was due to tumor cell dispersion, we carried out imaging of injected mammary glands to identify MCF10DCIS cells labeled with GFP. At 3 weeks after injection, we observed only a single primary lesion per injected gland in the nulliparous group, whereas the involution group showed additional smaller lesions at sites distant from the primary lesion (Fig. 2a) .
To assess the timing of tumor cell dispersion, at 3 d after injection we examined GFP-positive tumor cells by immunohistochemistry. Specific to the involution group, we detected tumor cells at high frequency throughout the mammary stroma ( Fig. 2b and Supplementary  Fig. 2a ) and in the mammary vasculature (Fig. 2c) . Extending these observations, flow cytometry analysis of peripheral blood showed increased circulating GFP-positive tumor cells at 3 d after tumor cell injection in the involution group only ( Fig. 2c and Supplementary  Fig. 2b ), demonstrating tumor cell access to the circulation during involution. Fluorescent in situ hybridization (FISH) analysis confirmed MCF10DCIS cell dispersion in the mammary stroma, mammary vasculature and mouse lung parenchyma unique to the involution group (Fig. 2d) .
To determine whether tumor cell infiltration of the lungs in the involution group was due to the increased size of primary tumors in this group, we quantified lung infiltration from mice with sizematched primary tumors using quantitative RT-PCR (qRT-PCR) for human-specific β2M transcripts. Compared to the tumors from the nulliparous group, those from the involution group had higher average human β2M expression in lung tissue, confirming that the increased invasive potential of involution group tumor cells is independent of tumor size (Fig. 2e) .
To distinguish whether the involution microenvironment alters the invasive potential of tumor cells in a manner that is maintained ex vivo, we examined GFP-positive tumor cell populations from involution and nulliparous groups. On average, tumor cell populations from the involution group were more proliferative (data not shown), and they showed increased motility (Fig. 2f ) and invasion (Fig. 2g) that were dependent on the presence of collagen I, as all cell populations were nonmotile and noninvasive on Matrigel (data not shown). Furthermore, the acquisition of motile behavior on collagen in tumor cells from the involution group was not dependent on primary tumor size, as tumor cells derived from smaller involution tumors were as motile as those derived from larger involution tumors (Fig. 2h) . These data implicate collagen I as a primary mediator of the increased proliferation, motility and invasion observed in involution group tumors.
Fibrillar collagen and COX-2 drive invasive phenotype
In vivo, we observed high expression of COX-2 in tumor cells located adjacent to high-density collagen (Fig. 3a) . Involution group tumors showed overall increased COX-2 expression (Fig. 3b) , and western blot analysis of pooled tumor cell lysates confirmed increased COX-2 protein expression in tumor cell populations isolated from involution group tumors (Fig. 3c) . In an in vitro wound-closure assay, tumor cell motility was reduced 50-80% with selective inhibition of COX-2 using the NSAID celecoxib (Fig. 3d) . We obtained further evidence that tumor cell interaction with collagen I induces COX-2 in three-dimensional culture, in which COX-2 expression in MCF10DCIS cells correlated directly with collagen I concentration ( Fig. 3e and Supplementary Fig. 3a) . Increasing COX-2 expression also correlated with increased invasive morphology (Fig. 3e,f and Supplementary Fig. 3b,c) , consistent with a role for COX-2 in mediating invasion on collagen. Supporting these observations, both treatment with celecoxib and shRNA knockdown of COX-2 resulted in a decrease in tumor cell invasive morphology observed on collagen (Fig. 3g,h and Supplementary Fig. 3d) .
Studies by others suggest that mammary tumor cell invasion and access to the vasculature is gained through migration along collagen fibers 18, 46 . Furthermore, radial alignment of collagen is characteristic of tumor-associated collagen and is implicated in tumor cell invasion 46 . Evaluation of collagen organization during involution revealed that collagen fibers were aligned radially to ducts in the involution group at almost twice the frequency observed in the nulliparous group (0.94 versus 0.58 radially aligned fibers per duct analyzed) (Fig. 3i) . Consistent with these data, induction of invasion in vitro was dependent on fibrillar collagen, as denatured collagen (gelatin) was unable to induce tumor cell invasion (Fig. 3j) . Of note, cells on denatured collagen showed upregulated COX-2 expression but did not invade ( Supplementary Fig. 3e,f) , indicating that invasion is context dependent and requires both fibrillar collagen and COX-2. Our data suggest that the increased deposition of fibrillar collagen during involution directly increases COX-2 expression in tumor cells and, furthermore, that tumor cells require COX-2 to migrate along collagen fibers.
In vivo, specific inhibition of COX-2 during postpartum involution resulted in a reduction in tumor growth ( Fig. 4a and Supplementary  Fig. 4a ) and dispersion (Fig. 4b,c) , consistent with roles for COX-2 in tumor cell proliferation and invasion. Unexpectedly, COX-2 inhibition during involution also decreased collagen deposition in the mammary glands and the frequency of radial fibers, down to nulliparous amounts (0.81 versus 0.43 fibers per duct analyzed) (Fig. 4d,e and  Supplementary Fig. 4b ). These results suggest that COX-2 inhibitors block collagen fibrillogenesis during postpartum mammary gland involution, and directly target tumor cell COX-2 expression that results from interaction with collagen, as modeled in Figure 4f .
Collagen and COX-2 may influence postpartum breast cancer
To address whether the collagen and COX-2 pathway may have a role in postpartum breast cancer in women, we analyzed collagen deposition and orientation in the breast tissue of young women. In comparison to breast tissue from nulliparous women, involuting breast tissue showed increased deposition of collagen and more than twice the frequency of radially aligned fibers (0.43 versus 1.0 radially aligned fibers per duct analyzed) (Fig. 5a,b and Supplementary  Fig. 5a,b) . On the basis of these observations and the link between collagen and tumor cell COX-2 expression described above, we examined whether collagen I and COX-2 expression correlate with early relapse in young women with breast cancer. We restricted these analyses to women ≤45 years of age, on the basis of a previous definition of young women's breast cancer 47 and recent data generated from our Young Women's Breast Cancer Translation Program clinical data set showing that ~33% of women aged 45 or less with breast cancer are diagnosed within 6 years of giving birth (V.B. and P.S., unpublished data).
We analyzed 11 publicly available microarray data sets (details in Supplementary Table 1) , resulting in a combined data set consisting of 345 cases aged ≤45 years at diagnosis who relapsed within 5 years. In this data set, high COL1A1 and COX-2 (encoded by prostaglandinendoperoxide synthase 2 (PTGS2)) expression correlated with decreased relapse-free survival, with a hazard ratio of 1.45 (95% CI: 1.08-1.95, multivariate Cox proportional-hazards model) that was independent of estrogen receptor status ( Fig. 5c and Supplementary  Fig. 5c,d) . Notably, high COL1A1 or COX-2 expression alone, or any other combination of COL1A1 and COX-2 expression, did not correlate with early relapse in univariate Cox proportionalhazards models ( Fig. 5d and Supplementary Fig. 5d ). This result is consistent with our in vitro data, which showed a requirement for both fibrillar collagen and COX-2 in driving cellular invasion ( Supplementary Fig. 3e,f) . Furthermore, in the NKI295 data set, high COL1A1 and COX-2 expression positively correlated with an activated wound response-gene expression signature previously shown to associate with decreased metastasis-free and overall survival in subjects with breast cancer 48 ( Supplementary Fig. 5e ). Last, in a small independent data set, analysis of DCIS lesions in nulliparous and postpartum women showed increased COX-2 protein expression in the postpartum DCIS lesions (Fig. 5e,f and Supplementary Fig. 5f ). These correlative results provide an impetus for further study into the role of collagen and COX-2 in human postpartum breast cancer.
Ibuprofen suppresses tumor progression during involution
Having identified COX-2 as a potential mediator of postpartum breast cancer, we tested whether ibuprofen, a safer NSAID than celecoxib for postpartum women, could decrease tumor promotion in rodents. In vitro, ibuprofen blocked motility of the highly invasive involution tumor cell populations by ~80% (Fig. 6a) . Furthermore, as observed with celecoxib in mice, treatment of rats with ibuprofen during involution reduced mammary gland collagen deposition and the frequency of radial fibers to nulliparous amounts (0.98 versus 0.33 radially aligned fibers per duct analyzed) ( Fig. 6b and Supplementary Fig. 6a ). To assess the efficacy of ibuprofen in the postpartum breast cancer model, we treated mice in the involution group with ibuprofen or empty vehicle for 14 d after weaning (Supplementary Fig. 6b ). Ibuprofen treatment did not affect the regression of the mammary epithelium that occurs during postpartum involution (Fig. 6c) or nulliparous group tumor growth ( Fig. 6d and Supplementary Fig. 6c ). However, in mice undergoing involution, ibuprofen treatment mitigated the increased tumor growth and COX-2 expression to nulliparous levels ( Fig. 6d-f and Supplementary Fig. 6d,e) and reduced tumor cell infiltration of the lung (Fig. 6g,h and Supplementary Fig. 6f ).
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DISCUSSION
Given the functional plasticity of the adult mammary gland, breast tumors are exposed to distinct microenvironments that may alter the progression and outcome of the disease. Here we investigated the effect of postpartum mammary gland involution on DCIS progression. The process of postpartum involution utilizes aspects of wound healing programs that are known to be tumor promotional [14] [15] [16] [17] , which may account for the increased metastasis observed in breast cancers following pregnancy [4] [5] [6] [7] [8] 17, [49] [50] [51] . Our studies build on previous work showing that tumors are promoted by postpartum mammary gland involution 9,13,52 and specifically by extracellular matrix proteins isolated from involuting mammary glands 9, 13 . We demonstrate a mechanism for involution-induced breast tumor progression that involves interaction between fibrillar collagen and COX-2, two established tumor-promotional molecules that have not previously been linked in the breast 18, 19, 21, 31, 32, [37] [38] [39] [40] 46, 53 . We demonstrate that COX-2 activity in the normal involuting gland is required for the deposition of fibrillar collagen and that this collagen upregulates COX-2 expression in tumor cells. Supporting this link, normal mouse mammary epithelial cells cultured in high-density collagen upregulate COX-2 mRNA approximately fourfold 21 , and prostaglandin E receptor 2, a product of COX-2 activity, promotes collagen production during wound healing in skin 54 . Thus, we identify two distinct roles for COX-2 in the promotion of breast tumors during involution: COX-2 activity in the host promotes mammary collagen fibrillogenesis and COX-2 activity in the tumor cell promotes invasion. We also report that collagen associated with physiologically normal postpartum involution has radial alignment, an organization previously observed only in invasive breast tumors 46 . Recently, radially aligned collagen was demonstrated to be an independent poor prognostic indicator in breast cancer 55 . We propose that radial collagen architecture in the involuting gland provides tracks by which COX-2-expressing tumor cells exit the duct, migrate into surrounding stroma and intravasate, similar to collagen-mediated tumor cell migration observed in other models 18, 19, 21, 46, 53 . Unexpectedly, COX-2 inhibition by NSAIDs during normal postpartum mammary gland involution blocked production and radial organization of fibrillar collagen. This observation suggests that modulation of collagen fibrillogenesis is a previously unidentified mechanism by which NSAIDs exhibit antitumor activity.
Notably, our data compiled from human breast tissues are consistent with the idea that the collagen and COX-2 pathway contributes to the poor prognosis of women with postpartum breast cancer. However, validation of these observations in larger cohorts would further test this hypothesis. Nonetheless, observations from our preclinical studies showing reduced tumor growth and metastatic potential with ibuprofen and celecoxib suggest that further research into COX-2 inhibitor use might provide a new strategy to improve the prognosis of young women should they be diagnosed with postpartum breast cancer. In support of this strategy, we provide evidence that ibuprofen does not interfere with normal postpartum gland regression. Further, relevance to chemoprevention in recently pregnant women at high risk for breast cancer is evident, as ibuprofen is a safe, affordable, over-the-counter NSAID and the duration of the treatment would be limited. A question that remains unexplored in our studies is whether an NSAID-based chemoprevention strategy can reduce incidence of postpartum breast cancer-a desirable objective given the 6 million pregnancies per year in the US.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
